Loading...

We've got a brand new version of Simply Wall St! Try it out

Matica Enterprises

CNSX:MMJ
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MMJ
CNSX
CA$16M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Matica Enterprises Inc. engages in the medical marijuana business. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Matica Enterprises has significant price volatility in the past 3 months.
MMJ Share Price and Events
7 Day Returns
0%
CNSX:MMJ
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-70.6%
CNSX:MMJ
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
MMJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Matica Enterprises (MMJ) 0% -9.1% -33.3% -70.6% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • MMJ underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • MMJ underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
MMJ
Industry
5yr Volatility vs Market

Value

 Is Matica Enterprises undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Matica Enterprises. This is due to cash flow or dividend data being unavailable. The share price is CA$0.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Matica Enterprises's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Matica Enterprises's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MMJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.01
CNSX:MMJ Share Price ** CNSX (2019-09-20) in CAD CA$0.05
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Matica Enterprises.

CNSX:MMJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MMJ Share Price ÷ EPS (both in CAD)

= 0.05 ÷ -0.01

-4.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Matica Enterprises is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Matica Enterprises is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Matica Enterprises's expected growth come at a high price?
Raw Data
CNSX:MMJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Matica Enterprises, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Matica Enterprises's assets?
Raw Data
CNSX:MMJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.05
CNSX:MMJ Share Price * CNSX (2019-09-20) in CAD CA$0.05
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:MMJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MMJ Share Price ÷ Book Value per Share (both in CAD)

= 0.05 ÷ 0.05

1.04x

* Primary Listing of Matica Enterprises.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Matica Enterprises is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Matica Enterprises's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Matica Enterprises has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Matica Enterprises expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Matica Enterprises has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Matica Enterprises expected to grow at an attractive rate?
  • Unable to compare Matica Enterprises's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Matica Enterprises's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Matica Enterprises's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:MMJ Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MMJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MMJ Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 -1 -4
2019-03-31 -1 -3
2018-12-31 -1 -5
2018-09-30 -1 -6
2018-06-30 -1 -6
2018-03-31 0 -6
2017-12-31 0 -4
2017-09-30 0 -2
2017-06-30 0 -1
2017-03-31 0 -1
2016-12-31 0 -1
2016-09-30 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Matica Enterprises is high growth as no earnings estimate data is available.
  • Unable to determine if Matica Enterprises is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MMJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Matica Enterprises Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MMJ Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.03
2017-12-31 -0.02
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Matica Enterprises will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Matica Enterprises's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Matica Enterprises's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Matica Enterprises's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Matica Enterprises's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Matica Enterprises has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Matica Enterprises performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Matica Enterprises's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Matica Enterprises does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Matica Enterprises's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Matica Enterprises's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Matica Enterprises's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Matica Enterprises Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MMJ Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -3.53 2.39
2019-03-31 -2.96 2.53
2018-12-31 -5.26 5.45
2018-09-30 -5.60 8.26
2018-06-30 -6.12 8.23
2018-03-31 -6.39 7.97
2017-12-31 -3.90 4.99
2017-09-30 -1.85 1.70
2017-06-30 -0.93 0.70
2017-03-31 -1.03 0.80
2016-12-31 -0.99 0.72
2016-09-30 -1.29 0.63
2016-06-30 -1.58 0.82
2016-03-31 -2.67 1.19
2015-12-31 -3.20 1.69
2015-09-30 -3.43 1.85 0.40
2015-06-30 -3.62 2.21 0.40
2015-03-31 -2.52 1.81 0.40
2014-12-31 -1.83 1.18 0.40
2014-09-30 -1.59 1.15
2014-06-30 -0.96 0.53
2014-03-31 -0.86 0.45
2013-12-31 -0.97 0.55
2013-09-30 -0.53 0.43
2013-06-30 -0.55 0.45
2013-03-31 -0.57 0.47
2012-12-31 -0.43 0.32
2012-09-30 -0.35 0.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Matica Enterprises has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Matica Enterprises has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Matica Enterprises improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Matica Enterprises's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Matica Enterprises has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Matica Enterprises's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Matica Enterprises's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Matica Enterprises is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Matica Enterprises has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Matica Enterprises's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Matica Enterprises has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Matica Enterprises Company Filings, last reported 2 months ago.

CNSX:MMJ Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 15.25 0.00 6.90
2019-03-31 15.50 0.00 7.56
2018-12-31 14.45 0.12 7.13
2018-09-30 15.47 0.01 8.96
2018-06-30 14.98 0.01 9.19
2018-03-31 13.96 0.03 8.54
2017-12-31 8.48 0.01 4.86
2017-09-30 3.33 0.04 1.45
2017-06-30 1.75 0.03 0.99
2017-03-31 0.27 0.02 0.39
2016-12-31 -0.12 0.03 0.14
2016-09-30 -0.22 0.01 0.12
2016-06-30 -0.05 0.01 0.02
2016-03-31 -0.02 0.01 0.03
2015-12-31 -0.21 0.01 0.09
2015-09-30 0.04 0.00 0.02
2015-06-30 0.52 0.00 0.06
2015-03-31 1.43 0.00 0.12
2014-12-31 0.78 0.03 0.12
2014-09-30 -0.01 0.00 0.03
2014-06-30 -0.16 0.00 0.11
2014-03-31 -0.22 0.00 0.01
2013-12-31 -0.21 0.00 0.00
2013-09-30 0.17 0.00 0.00
2013-06-30 0.17 0.00 0.01
2013-03-31 -0.05 0.00 0.08
2012-12-31 0.03 0.00 0.14
2012-09-30 0.07 0.00 0.06
  • Matica Enterprises has no debt.
  • Matica Enterprises currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Matica Enterprises has sufficient cash runway for more than 3 years based on current free cash flow.
  • Matica Enterprises has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 3.4% each year.
X
Financial health checks
We assess Matica Enterprises's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Matica Enterprises has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Matica Enterprises's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Matica Enterprises dividends.
If you bought CA$2,000 of Matica Enterprises shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Matica Enterprises's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Matica Enterprises's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MMJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Matica Enterprises has not reported any payouts.
  • Unable to verify if Matica Enterprises's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Matica Enterprises's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Matica Enterprises has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Matica Enterprises's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Matica Enterprises afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Matica Enterprises has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Matica Enterprises's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Boris Ziger
COMPENSATION CA$1,053,400
TENURE AS CEO 7 years
CEO Bio

Mr. Boris Ivan Ziger, HBA, MBA, has been the Chief Executive Officer at Matica Enterprises Inc. since September 2012 and also its Director since March 1, 2012 and serves as its Chairman of the Board. Mr. Ziger has been a Corporate Communications Advisor of Cavan Ventures Inc. since June 7, 2011. He provides corporate communications and investor relations activities including introducing Cavan to potential investors. He has twenty years of experience. He served as a Senior Officer of public companies. He served as the President and Corporate Development Advisor of Stellar Pacific Ventures Inc. Mr. Ziger served as the President of World Organics Inc. until June 2, 2008. He served as President of Manning Environmental from 2003 to 2005 and Stockbroker with IPO Capital from 1993 to 2003. He served as President of Gold World Resources Inc. from February 2006 to April 2007 and as its Chief Financial Officer from December 2006 to April 2007. He worked as Senior Account Executive and Senior Investment Advisor in Investment industry since 1993, where he assisted companies to gain access to capital markets and in the evaluation of new projects. He has been a Director of Matica Enterprises Inc. since March 1, 2012. Mr. Ziger has been an Independent Director of FTI Foodtech International Inc. since July 2010 until September 14, 2016. He served as a Director of Stellar Pacific Ventures Inc. He served as a Director of World Organics Inc., until June 2, 2008. He served as a Director of Gold World Resources Inc. from November 8, 2005 to June 2, 2008. He served as a Director of public companies. Mr. Ziger holds a Master of Business Administration degree from Odette School of Business and Honours Bachelor of Arts degree in Economics and Psychology from York University.

CEO Compensation
  • Boris's compensation has increased whilst company is loss making.
  • Boris's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Matica Enterprises management team in years:

3.9
Average Tenure
  • The tenure for the Matica Enterprises management team is about average.
Management Team

Boris Ziger

TITLE
Chairman & CEO
COMPENSATION
CA$1M
TENURE
7 yrs

George Brown

TITLE
Interim CFO & Director
COMPENSATION
CA$975K
AGE
63
TENURE
3.9 yrs

Don Shaxon

TITLE
Vice President of Corporate Development
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure of the Matica Enterprises board of directors in years:

3.3
Average Tenure
  • The tenure for the Matica Enterprises board of directors is about average.
Board of Directors

Boris Ziger

TITLE
Chairman & CEO
COMPENSATION
CA$1M

George Brown

TITLE
Interim CFO & Director
COMPENSATION
CA$975K
AGE
63
TENURE
4.3 yrs

Charn Deol

TITLE
Director
COMPENSATION
CA$462K
AGE
69
TENURE
2.5 yrs

Ryan Brown

TITLE
Member of Advisory Board
TENURE
4.1 yrs

Meissam Panah

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Matica Enterprises individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
28. Jul 19 Sell Boris Ziger Individual 22. Jul 19 22. Jul 19 -100,000 CA$0.08 CA$-7,500
29. May 19 Sell Boris Ziger Individual 13. May 19 13. May 19 -200,000 CA$0.09 CA$-18,000
22. Apr 19 Sell Boris Ziger Individual 16. Apr 19 16. Apr 19 -100,000 CA$0.10 CA$-9,500
10. Apr 19 Sell Gurcharn Deol Individual 10. Apr 19 10. Apr 19 -61,000 CA$0.10 CA$-6,100
29. Mar 19 Sell Gurcharn Deol Individual 27. Mar 19 27. Mar 19 -30,000 CA$0.10 CA$-3,000
25. Mar 19 Sell Denis Bouchard Individual 21. Mar 19 21. Mar 19 -13,111 CA$0.10 CA$-1,377
20. Mar 19 Sell Boris Ziger Individual 15. Mar 19 15. Mar 19 -100,000 CA$0.11 CA$-10,500
01. Mar 19 Sell Denis Bouchard Individual 26. Feb 19 26. Feb 19 -8,000 CA$0.12 CA$-960
25. Feb 19 Sell Denis Bouchard Individual 22. Feb 19 22. Feb 19 -90,000 CA$0.12 CA$-10,800
04. Feb 19 Sell Boris Ziger Individual 31. Jan 19 31. Jan 19 -100,000 CA$0.13 CA$-13,000
25. Jan 19 Sell Gurcharn Deol Individual 23. Jan 19 23. Jan 19 -20,111 CA$0.15 CA$-3,017
15. Jan 19 Sell George Brown Individual 10. Jan 19 10. Jan 19 -910,000 CA$0.11 CA$-100,101
02. Jan 19 Sell Boris Ziger Individual 27. Dec 18 27. Dec 18 -100,000 CA$0.08 CA$-7,500
15. Oct 18 Sell Boris Ziger Individual 09. Oct 18 09. Oct 18 -50,000 CA$0.18 CA$-8,750
X
Management checks
We assess Matica Enterprises's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Matica Enterprises has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can You Imagine How Elated Matica Enterprises's (CNSX:MMJ) Shareholders Feel About Its 650% Share Price Gain?

As long term investors the recent fall doesn't detract all that much from the longer term story. … It seems likely some shareholders believe that Matica Enterprises will significantly advance the business plan before too long. … If you would like to research Matica Enterprises in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

Matica Enterprises Inc. (CNSX:MMJ) Insiders Have Been Selling

So we'll take a look at whether insiders have been buying or selling shares in Matica Enterprises Inc. … Matica Enterprises Insider Transactions Over The Last Year. … While we don't usually like to see insider selling, it's more concerning if the sales take price at a lower price

Simply Wall St -

Company Info

Description

Matica Enterprises Inc. engages in the medical marijuana business. It offers IONIC MIST, a spray mist that captures cannabis smoke odors. The company was formerly known as Matica Graphite Inc. and changed its name to Matica Enterprises Inc. in July 2014. Matica Enterprises Inc. is based in Toronto, Canada.

Details
Name: Matica Enterprises Inc.
MMJ
Exchange: CNSX
Founded:
CA$15,843,938
316,878,779
Website: http://www.maticaenterprises.com
Address: Matica Enterprises Inc.
44 Victoria Street,
Suite 1102,
Toronto,
Ontario, M5C 1Y2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MMJ Common Shares Canadian National Stock Exchange CA CAD 10. Jul 2008
OTCPK MMJF.F Common Shares Pink Sheets LLC US USD 10. Jul 2008
DB 39N Common Shares Deutsche Boerse AG DE EUR 10. Jul 2008
Number of employees
Current staff
Staff numbers
0
Matica Enterprises employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:37
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.